Easterling To Focus On Enhancing The Company’s Proprietary Cannabinoid Formulations With Amazonian Plants For Further Benefit
DENVER, April 02, 2019 (GLOBE NEWSWIRE) -- United Cannabis Corporation (CNAB) (the “Company” or “United Cannabis”) today announced that it has entered into a Partnership with John Easterling, environmentalist and founder of the multi-million dollar Amazon Herb Company, to create and produce formulations that combine the health benefits of cannabinoids with botanicals from the Amazonian Rainforest.
Mr. Easterling turned a fascination with South America into a lifelong pursuit. His first years were spent seeking and trading tribal artifacts on behalf of museums and collectors, when a long bout with hepatitis and Rocky Mountain spotted fever left him gravely ill. He soon found himself under the care of the Shipibo tribe in the Amazon rainforest, who gave him a homeopathic herbal tea that cured him within days. Since that time, Mr. Easterling has been dedicated to the exploration and preservation of the rainforest.
Mr. Easterling co-founded Amazon Herb Company to develop and market healing remedies that rely on the plants of the rainforest on a socially responsible basis. In 2012, it merged with the global wellness company TriVita, based in Arizona.
Mr. Easterling will use his expertise to develop proprietary formulations that leverage the health benefits found in the plants of the rainforest with United Cannabis’ patented cannabinoid formulations and delivery mechanisms to create medicines for a variety of conditions. He will receive a royalty on the sales derived from products created through the partnership.
Earnest Blackmon, Chief Executive Officer of United Cannabis, commented on the announcement, “We’ve built United Cannabis on the philosophy that plants offer significant medical benefit, a view that John shares. His knowledge and insight regarding the opportunities for synergies between rainforest botanicals and cannabinoids will be invaluable as we seek to develop new medical therapies to complement our Prana Bio Nutrient Medicinals and Industrial Hemp product lines.”
Mr. Easterling added, “The Amazon is home to the largest and most bio-diverse tropical rainforest in the world. The plants found there have some of the most powerful analgesic, antioxidant, anti-inflammatory and detoxifying properties available, and I have spent my life creating products that bring those benefits to patients across the globe. I believe that cannabinoids are making equally powerful contributions to our general health and wellness, and I look forward to working with the team at United Cannabis to create formulations that leverage the benefits of both of these resources.”
About United Cannabis Corporation
United Cannabis Corporation is a biotechnology company dedicated to the development of phyto-therapeutic based products supported by patented technologies for the pharmaceutical, medical, and industrial markets. The Company has long advocated the application of cannabinoids for medical applications and is building a platform for designing targeted therapies to increase the quality of life for patients around the world. Most of the Company’s products are patent protected first in class medicines with applications to a global market. United Cannabis trades on the OTCQB under the symbol CNAB.
For further information, please visit www.unitedcannabis.us.
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933, are subject to Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbors created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and future results and events could differ materially from those anticipated in such statements.